Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

231

Participants

Timeline

Start Date

April 30, 2010

Primary Completion Date

April 30, 2012

Study Completion Date

December 31, 2012

Conditions
Diarrhoea
Interventions
DRUG

VSL#3

Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.

DRUG

Placebo

Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.

Trial Locations (5)

WN1 2NN

Royal Albert Edward Infirmary, Wigan

SE18 4QH

Queen Elizabeth Hospital, Woolwich

BS16 1LE

Frenchay Hospital, Bristol

HU3 2JZ

Hull Royal Infirmary, Hull

BS23 4TQ

Weston General Hospital, Weston-super-Mare

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Wrightington, Wigan and Leigh NHS Foundation Trust

OTHER

collaborator

Ferring Pharmaceuticals

INDUSTRY

collaborator

South London and Maudsley NHS Foundation Trust

OTHER

collaborator

North Bristol NHS Trust

OTHER

collaborator

Hull University Teaching Hospitals NHS Trust

OTHER_GOV

lead

National Health Service, United Kingdom

OTHER_GOV

NCT00973908 - Probiotics for the Prevention of Antibiotics Associated Diarrhoea and Clostridium Difficile Associated Diarrhoea | Biotech Hunter | Biotech Hunter